Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.
Identifieur interne : 000192 ( PubMed/Checkpoint ); précédent : 000191; suivant : 000193Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.
Auteurs : Michel Panisset ; Jean-Louis Stril ; Manon Bélanger ; Geneviève Lehoux ; Donna Coffin ; Sylvain ChouinardSource :
- The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques [ 0317-1671 ] ; 2016.
English descriptors
- KwdEn :
- Aged, Dose-Response Relationship, Drug, Female, Humans, Indans (therapeutic use), Male, Middle Aged, Neuroprotective Agents (therapeutic use), Parkinson Disease (complications), Psychiatric Status Rating Scales, Retrospective Studies, Severity of Illness Index, Sleep Wake Disorders (drug therapy), Sleep Wake Disorders (etiology), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Indans, Neuroprotective Agents.
- complications : Parkinson Disease.
- drug therapy : Sleep Wake Disorders.
- etiology : Sleep Wake Disorders.
- Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Retrospective Studies, Severity of Illness Index, Treatment Outcome.
Abstract
The prevalence of sleep disturbances among patients with Parkinson's disease (PD) is estimated to occur in 37% to 98% of patients. Sleep disturbances have been associated with a reduced quality of life for patients with PD. The objective of this study was to assess the impact of rasagiline treatment on the severity of sleep disturbances among patients with idiopathic PD.
DOI: 10.1017/cjn.2016.289
PubMed: 27827298
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:27827298Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.</title><author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name><affiliation><nlm:affiliation>1Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center) and Centre de recherche du Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center Research Center) Hôpital Notre-Dame,Département de médecine (Neurologie) Université de Montréal,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Stril, Jean Louis" sort="Stril, Jean Louis" uniqKey="Stril J" first="Jean-Louis" last="Stril">Jean-Louis Stril</name><affiliation><nlm:affiliation>2former employees of TEVA Canada Innovation,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Belanger, Manon" sort="Belanger, Manon" uniqKey="Belanger M" first="Manon" last="Bélanger">Manon Bélanger</name><affiliation><nlm:affiliation>2former employees of TEVA Canada Innovation,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Lehoux, Genevieve" sort="Lehoux, Genevieve" uniqKey="Lehoux G" first="Geneviève" last="Lehoux">Geneviève Lehoux</name><affiliation><nlm:affiliation>2former employees of TEVA Canada Innovation,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Coffin, Donna" sort="Coffin, Donna" uniqKey="Coffin D" first="Donna" last="Coffin">Donna Coffin</name><affiliation><nlm:affiliation>3Boolean Research Consulting Services,Montreal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name><affiliation><nlm:affiliation>1Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center) and Centre de recherche du Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center Research Center) Hôpital Notre-Dame,Département de médecine (Neurologie) Université de Montréal,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27827298</idno><idno type="pmid">27827298</idno><idno type="doi">10.1017/cjn.2016.289</idno><idno type="wicri:Area/PubMed/Corpus">000124</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000124</idno><idno type="wicri:Area/PubMed/Curation">000124</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000124</idno><idno type="wicri:Area/PubMed/Checkpoint">000124</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000124</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.</title><author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name><affiliation><nlm:affiliation>1Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center) and Centre de recherche du Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center Research Center) Hôpital Notre-Dame,Département de médecine (Neurologie) Université de Montréal,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Stril, Jean Louis" sort="Stril, Jean Louis" uniqKey="Stril J" first="Jean-Louis" last="Stril">Jean-Louis Stril</name><affiliation><nlm:affiliation>2former employees of TEVA Canada Innovation,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Belanger, Manon" sort="Belanger, Manon" uniqKey="Belanger M" first="Manon" last="Bélanger">Manon Bélanger</name><affiliation><nlm:affiliation>2former employees of TEVA Canada Innovation,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Lehoux, Genevieve" sort="Lehoux, Genevieve" uniqKey="Lehoux G" first="Geneviève" last="Lehoux">Geneviève Lehoux</name><affiliation><nlm:affiliation>2former employees of TEVA Canada Innovation,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Coffin, Donna" sort="Coffin, Donna" uniqKey="Coffin D" first="Donna" last="Coffin">Donna Coffin</name><affiliation><nlm:affiliation>3Boolean Research Consulting Services,Montreal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author><author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name><affiliation><nlm:affiliation>1Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center) and Centre de recherche du Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center Research Center) Hôpital Notre-Dame,Département de médecine (Neurologie) Université de Montréal,Montréal,Québec.</nlm:affiliation><wicri:noCountry code="subField">Québec</wicri:noCountry></affiliation></author></analytic><series><title level="j">The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</title><idno type="ISSN">0317-1671</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Indans (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Psychiatric Status Rating Scales</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Sleep Wake Disorders (drug therapy)</term><term>Sleep Wake Disorders (etiology)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Indans</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sleep Wake Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Sleep Wake Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Psychiatric Status Rating Scales</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The prevalence of sleep disturbances among patients with Parkinson's disease (PD) is estimated to occur in 37% to 98% of patients. Sleep disturbances have been associated with a reduced quality of life for patients with PD. The objective of this study was to assess the impact of rasagiline treatment on the severity of sleep disturbances among patients with idiopathic PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27827298</PMID><DateCreated><Year>2016</Year><Month>11</Month><Day>09</Day></DateCreated><DateCompleted><Year>2017</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0317-1671</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</Title><ISOAbbreviation>Can J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.</ArticleTitle><Pagination><MedlinePgn>809-814</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The prevalence of sleep disturbances among patients with Parkinson's disease (PD) is estimated to occur in 37% to 98% of patients. Sleep disturbances have been associated with a reduced quality of life for patients with PD. The objective of this study was to assess the impact of rasagiline treatment on the severity of sleep disturbances among patients with idiopathic PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this open-label, multicentre study, 110 adult patients with idiopathic PD were treated with rasagiline either as monotherapy or as adjunct therapy. The primary endpoint was the change in severity of sleep disturbances, assessed with the PD Sleep Scale from baseline to month 2. Exploratory endpoints included change in daytime sleepiness, assessed with the Epworth Sleep Scale, treatment satisfaction measured with the Treatment Satisfaction Questionnaire for Medication, patient's overall improvement or deterioration over time measured with the Clinical Global Impression of Improvement, tolerability, and safety.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Patients treated with rasagiline as mono- or adjunct therapy showed a statistically significant improvement in sleep quality after 2 months. There was no change in daytime sleepiness. Overall, patients were satisfied with rasagiline treatment with a mean Treatment Satisfaction Questionnaire for Medication [standard deviation] total score at month 2 of 68% [16.1]. At the end of study, 64 patients (65.9%) were judged, by the investigator, as being at least minimally improved from baseline on the Clinical Global Impression of Improvement. Rasagiline was safe and well-tolerated.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Rasagiline as mono- or adjunct-therapy may improve sleep experience in patients with PD in the short term.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panisset</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center) and Centre de recherche du Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center Research Center) Hôpital Notre-Dame,Département de médecine (Neurologie) Université de Montréal,Montréal,Québec.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stril</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>2former employees of TEVA Canada Innovation,Montréal,Québec.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bélanger</LastName><ForeName>Manon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2former employees of TEVA Canada Innovation,Montréal,Québec.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehoux</LastName><ForeName>Geneviève</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>2former employees of TEVA Canada Innovation,Montréal,Québec.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coffin</LastName><ForeName>Donna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>3Boolean Research Consulting Services,Montreal,Québec.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chouinard</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center) and Centre de recherche du Centre Hospitalier de l'Université de Montréal (University of Montreal Hospital Center Research Center) Hôpital Notre-Dame,Département de médecine (Neurologie) Université de Montréal,Montréal,Québec.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Neurol Sci</MedlineTA><NlmUniqueID>0415227</NlmUniqueID><ISSNLinking>0317-1671</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson disease</Keyword><Keyword MajorTopicYN="N">Rasagiline</Keyword><Keyword MajorTopicYN="N">Sleep</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27827298</ArticleId><ArticleId IdType="pii">S0317167116002894</ArticleId><ArticleId IdType="doi">10.1017/cjn.2016.289</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Belanger, Manon" sort="Belanger, Manon" uniqKey="Belanger M" first="Manon" last="Bélanger">Manon Bélanger</name><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name><name sortKey="Coffin, Donna" sort="Coffin, Donna" uniqKey="Coffin D" first="Donna" last="Coffin">Donna Coffin</name><name sortKey="Lehoux, Genevieve" sort="Lehoux, Genevieve" uniqKey="Lehoux G" first="Geneviève" last="Lehoux">Geneviève Lehoux</name><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name><name sortKey="Stril, Jean Louis" sort="Stril, Jean Louis" uniqKey="Stril J" first="Jean-Louis" last="Stril">Jean-Louis Stril</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000192 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000192 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:27827298
|texte= Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:27827298" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |